Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-12, Stock:NVS, The news for the past five days is as follows:
2018-02-05: NEWS1: Greek govt alleges official ties to drug bribery scandal.NEWS2: 3 Top Pharmaceutical Stocks to Buy Now.NEWS3: 3 Top Pharmaceutical Stocks to Buy Now.NEWS4: Novartis’s Valuations after Its 4Q17 Earnings.NEWS5: Novartis’s 4Q17 Earnings: Alcon Business.NEWS6: GSK Is Focused on Innovative Assets in Oncology Research Pipeline.NEWS7: Novartis’s 4Q17 Earnings: Sandoz Business.NEWS8: How Biogen’s Biosimilars and Interferons Performed in 4Q17.NEWS9: Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline.NEWS10: The Swiss Stock Market Continues To Sell-Off.NEWS11: The Swiss Stock Market Continues To Sell-Off.
2018-02-06: NEWS1: Roche Reports Positive Data From Tecentriq-Avastin Study.NEWS2: Roche Reports Positive Data From Tecentriq-Avastin Study.NEWS3: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS4: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS5: The Diseases We Aren’t Curing—And Why.NEWS6: How Did Kalydeco Perform in 4Q17 and 2017?.NEWS7: Analysts’ Recommendations for Novartis after Its 4Q17 Earnings.NEWS8: The Swiss Stock Market Sank Below The 9,000 Point Level.NEWS9: The Swiss Stock Market Sank Below The 9,000 Point Level.NEWS10: Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall.NEWS11: Xtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall.
2018-02-07: NEWS1: Pfizer Inc. Stock Hurt by Dwindling Revenue Growth Prospects.NEWS2: Pfizer Inc. Stock Hurt by Dwindling Revenue Growth Prospects.NEWS3: Array's Melanoma Combo Shows Positive Overall Survival Data.NEWS4: Array's Melanoma Combo Shows Positive Overall Survival Data.NEWS5: The Swiss Stock Market Regained Some Lost Ground.NEWS6: The Swiss Stock Market Regained Some Lost Ground.NEWS7: New Drugs Approved In January.NEWS8: New Drugs Approved In January.
2018-02-08: NEWS1: Top Research Reports for Novartis, BP & Biogen.NEWS2: Top Research Reports for Novartis, BP & Biogen.NEWS3: How Pfizer’s Business Segments Performed in 4Q17.NEWS4: Pfizer Reports Revenue Growth in 4Q17.NEWS5: Top Research Reports for Novartis, BP & Biogen.NEWS6: Amgen’s Repatha and Blincyto: How They Did in 3Q17.NEWS7: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS8: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS9: Novartis&apos; Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS10: Imbruvica Leads in the Chronic Lymphocytic Leukemia Space.NEWS11: Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000.NEWS12: The Swiss Stock Market Dropped To Its Lowest Level Since April.NEWS13: The Swiss Stock Market Dropped To Its Lowest Level Since April.NEWS14: Glaxo's Key Drug Gains Time as FDA Denies Novartis Generic.NEWS15: Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed.NEWS16: Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts.NEWS17: Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts.
2018-02-09: NEWS1: [$$] Novartis Faces Investigation For Alleged Bribery In Greece.NEWS2: What’s Expected of Novartis’s Core Operating Income in 2018?.NEWS3: Why Novartis Is Expected to Report Modest Revenue Growth in 2018.NEWS4: Novartis and Peers in February 2018: Analyst Recommendations.NEWS5: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS6: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS7: Analyst: Regeneron Is Undervalued By The Street.NEWS8: A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17.NEWS9: Why Sanofi Has Received a Negative Outlook from Fitch Ratings.NEWS10: Will Teva Pharmaceutical's Pain Be Mylan's Gain?.NEWS11: Will Teva Pharmaceutical's Pain Be Mylan's Gain?.NEWS12: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS13: How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy.NEWS14: How Amgen’s Xgeva and Prolia Performed in 4Q17.NEWS15: Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform.NEWS16: The Swiss Stock Market Ends Another Turbulent Session In The Red.NEWS17: The Swiss Stock Market Ends Another Turbulent Session In The Red.

Answer: Rise